

PB 96 of 2025

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 8)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 98C(1) of the *National Health Act 1953*.

Dated 29 August 2025

REBECCA RICHARDSON

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division

Conte	nts		
	1	Name	1
	2	Commencement	1
	3	Authority	1
	4	Schedules	1
Schedule	e 1—Amo	endments	2
	National H for Supply (ealth (Commonwealth Price and Conditions for Commonwealth Payments of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)	2

1 Name

- (1) This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 8).
- (2) This instrument may also be cited as PB 96 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information						
Column 1	Column 2	Column 3				
Provisions	Commencement	Date/Details				
1. The whole of this instrument	1 September 2025	1 September 2025				

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 98C(1) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

	inser	<i>t</i> ·	
[5]			after entry for Methylphenidate in the form Capsule containing date hydrochloride 60 mg (modified release)
Methylph	nenida	te	Capsule containing methylphenidate hydrochloride 30 mg (modified release) (s19A)
	meth inser	• .	date hydrochloride 30 mg (modified release)
[4]			after entry for Methylphenidate in the form Capsule containing
Methylph	nenida	te	Capsule containing methylphenidate hydrochloride 20 mg (modified release (s19A)
[3]	Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 20 mg (modified release) insert:		
Methylph	nenida	te	Capsule containing methylphenidate hydrochloride 10 mg (modified release) (s19A)
	inser		
[2]			after entry for Methylphenidate in the form Capsule containing date hydrochloride 10 mg (modified release)
Fentanyl			Transdermal patch 16.5 mg
	(e)	omit:	
Fentanyl			Transdermal patch 12.375 mg
Fentanyl	` ,		Transdermal patch 10.20 mg
	(d)	omit:	1 6
Fentanyl			Transdermal patch 8.25 mg
Fentanyl Fentanyl			Transdermal patch 5.10 mg Transdermal patch 7.65 mg
Esutsual	(c)	omit:	Transfermed notely 5 10 mm
Fentanyl			Transdermal patch 4.125 mg
Fentanyl			Transdermal patch 2.55 mg
	(b)	omit:	
Fentanyl			Transdermal patch 2.063 mg
Fentanyl			Transdermal patch 1.28 mg
	(a)	omit:	

Methylphenidate		Capsule containing methylphenidate hydrochloride 60 mg (modified release) (s19A)
[6]	Schedule 3	3, entries for Morphine
Morphine		Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (S19A)
Morphine		Oral solution containing morphine sulfate 2 mg per mL in 100 mL bottle, 1 mL (S19A)
Morphine		Oral solution containing morphine sulfate 2 mg per mL in 500 mL bottle, 1 mL (S19A)